Metformin-based glucose-lowering regimens, circulating biomarkers, and exploratory muscle outcomes in type 2 diabetes: a cross-sectional study
Metformin-basierte glukosesenkende Regime, zirkulierende Biomarker und explorative Muskel-Outcomes bei Typ-2-Diabetes: eine Querschnittsstudie
Frontiers in Medicine · 04.11.2026 · 13
DOI: 10.3389/fmed.2026.1998468 ↗Auf einen Blick
Bei 161 Erwachsenen mit Typ-2-Diabetes wurden drei stabile Metformin-Regime verglichen. Unter Empagliflozin fanden sich in den Primäranalysen niedrigere TNF-α-Spiegel und höhere IGF-1-Spiegel als unter Metformin allein.
Fragestellung
Unterscheiden sich Muskelphänotypen sowie IGF-1 und TNF-α zwischen Metformin allein, Metformin plus Dulaglutid und Metformin plus Empagliflozin bei Erwachsenen mit Typ-2-Diabetes?
Methode
Einzentrische Querschnittsstudie mit 161 Patient:innen; Vergleich von Metformin, Metformin plus Dulaglutid und Metformin plus Empagliflozin. Primäranalysen mit Anpassung für Alter, Geschlecht, Diabetesdauer, BMI, HbA1c und eGFR.
Ergebnisse
Gruppen: 52, 54 und 55 Patient:innen. BIA-SMI, Handkraft, körperliche Leistung und Sarkopenieprävalenz unterschieden sich nicht. Empagliflozin vs. Metformin: IGF-1 +7,50 ng/mL (95 %-KI 1,66 bis 13,34), TNF-α −3,09 pg/mL (95 %-KI −4,95 bis −1,24).
Einschränkungen
Behandlungswahlunterschiede, Residualkonfundierung und mögliche Hydratationsverzerrung der BIA schränken die Interpretation ein. Sarkopenievergleiche waren explorativ und durch wenige Fälle begrenzt.
Schlussfolgerung der Autor:innen
Niedrigere TNF-α-Konzentrationen wurden in der Empagliflozin-Gruppe gesehen; der IGF-1-Zusammenhang war unsicher. Für objektive Muskel-Outcomes zeigten sich keine signifikanten Unterschiede.
Kernaussagen
- Empagliflozin war mit niedrigerem TNF-α und höherem IGF-1 assoziiert
- Objektive Muskel-Outcomes unterschieden sich zwischen den Regimen nicht
- Die Befunde sind hypothesengenerierend und nicht kausal interpretierbar
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Querschnittstudie in der Zeitschrift Frontiers in Medicine, online erschienen am 04.11.2026. Verfasst von Xiaoying Zhang und 7 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
To compare three stable metformin-based regimens—metformin alone, metformin plus dulaglutide, and metformin plus empagliflozin—in relation to muscle phenotypes and circulating insulin-like growth factor 1 (IGF-1) and tumor necrosis factor alpha (TNF-α) in adults with type 2 diabetes mellitus (T2DM).
Methods
This single-center cross-sectional study included 161 patients. Bioelectrical impedance analysis-derived skeletal muscle index (BIA-SMI), maximum handgrip strength, 6-m gait speed, five-times chair stand time, sarcopenia status, serum IGF-1, and serum TNF-α were assessed. Primary models adjusted for age, sex, diabetes duration, and the most recent body mass index, glycated hemoglobin, and estimated glomerular filtration rate recorded before regimen initiation, using HC3 heteroskedasticity-robust standard errors. IGF-1 and TNF-α were primary biomarker outcomes; BIA-SMI and handgrip strength were secondary exploratory outcomes. Holm correction, pairwise propensity score overlap weighting, restriction and log-transformation sensitivity analyses, and false discovery rate-adjusted Spearman correlations were used.
Results
The metformin, dulaglutide, and empagliflozin groups included 52, 54, and 55 patients, respectively. BIA-SMI, handgrip strength, physical performance, and sarcopenia prevalence did not differ significantly among groups. Compared with metformin, empagliflozin was associated with IGF-1 higher by 7.50 ng/mL (95% CI 1.66 to 13.34; Holm-adjusted P = 0.035) and TNF-α lower by 3.09 pg/mL (95% CI −4.95 to −1.24; Holm-adjusted P = 0.004). The overall handgrip-strength test was not significant ( P = 0.137); the empagliflozin-versus-metformin coefficient was 2.11 kg (nominal P = 0.047; Holm-adjusted P = 0.189) and was interpreted as exploratory. BIA-SMI was not associated with regimen (overall P = 0.739). After overlap weighting, the association with lower TNF-α persisted, whereas the IGF-1 difference was attenuated. Biomarker associations retained the same directions in log-transformed models. TNF-α was directionally consistent across restriction analyses, whereas the IGF-1 association weakened after exclusion of patients with chronic kidney disease.
Conclusion
Lower circulating TNF-α concentrations were observed in the empagliflozin group in the primary analyses, although this association was attenuated after additional adjustment for cardiovascular and renal comorbidities and statin use. The IGF-1 association was uncertain and may reflect kidney-related differences. No statistically significant differences were detected in the objective muscle outcomes, whereas SARC-F scores differed across groups, with the highest median score in the empagliflozin group. The patient-reported and performance-based findings did not provide consistent evidence of better or worse muscle-related function attributable to any regimen. Sarcopenia comparisons were exploratory and limited by the small number of cases. Treatment-selection differences, residual confounding, and potential hydration-related bias in BIA estimates limit interpretation. These findings are hypothesis-generating and do not establish independent drug effects on IGF-1, comparative treatment benefits, or equivalent muscle mass.
Zitieren
APA
Zhang, X., Wang, H., Hao, C., Shen, K., Deng, X., Li, Z., Kang, Z., & Mao, Y. (2026). Metformin-based glucose-lowering regimens, circulating biomarkers, and exploratory muscle outcomes in type 2 diabetes: a cross-sectional study. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1998468
Vancouver
Zhang X, Wang H, Hao C, Shen K, Deng X, Li Z, et al. Metformin-based glucose-lowering regimens, circulating biomarkers, and exploratory muscle outcomes in type 2 diabetes: a cross-sectional study. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1998468
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoying and Wang, Huanhuan and Hao, Cong and Shen, Kaiyue and Deng, Xinyu and Li, Zheyu and Kang, Zhiqiang and Mao, Yu},
title = {Metformin-based glucose-lowering regimens, circulating biomarkers, and exploratory muscle outcomes in type 2 diabetes: a cross-sectional study},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1998468}
}
EUVIMED